ABERA BIOSCIENCE AB (8WK) - Net Assets
Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) has net assets worth €19.29 Million EUR (≈ $22.55 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€28.57 Million ≈ $33.40 Million USD) and total liabilities (€9.28 Million ≈ $10.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of ABERA BIOSCIENCE AB for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.29 Million |
| % of Total Assets | 67.51% |
| Annual Growth Rate | 4.75% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 78.08 |
ABERA BIOSCIENCE AB - Net Assets Trend (2022–2025)
This chart illustrates how ABERA BIOSCIENCE AB's net assets have evolved over time, based on quarterly financial data. Also explore 8WK total asset value for the complete picture of this company's asset base.
Annual Net Assets for ABERA BIOSCIENCE AB (2022–2025)
The table below shows the annual net assets of ABERA BIOSCIENCE AB from 2022 to 2025. For live valuation and market cap data, see ABERA BIOSCIENCE AB market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €19.29 Million ≈ $22.55 Million |
+122.80% |
| 2024-12-31 | €8.66 Million ≈ $10.12 Million |
+53.07% |
| 2023-12-31 | €5.66 Million ≈ $6.61 Million |
-66.30% |
| 2022-12-31 | €16.78 Million ≈ $19.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ABERA BIOSCIENCE AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2780375300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €91.20 Million | 472.87% |
| Total Equity | €19.29 Million | 100.00% |
ABERA BIOSCIENCE AB Competitors by Market Cap
The table below lists competitors of ABERA BIOSCIENCE AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clean & Science co. Ltd
KQ:045520
|
$11.57 Million |
|
Lion Metal Works Tbk
JK:LION
|
$11.58 Million |
|
Dome Gold Mines Ltd
AU:DME
|
$11.59 Million |
|
Kwang Jin Ind. Co. Ltd
KQ:026910
|
$11.59 Million |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
$11.55 Million |
|
Garibaldi Resources Corp.
V:GGI
|
$11.55 Million |
|
Sahathai Terminal Public Company Limited
BK:PORT
|
$11.54 Million |
|
Arita Prima Indonesia Tbk
JK:APII
|
$11.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABERA BIOSCIENCE AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,656,000 to 19,286,000, a change of 10,630,000 (122.8%).
- Net loss of 10,453,000 reduced equity.
- New share issuances of 21,500,000 increased equity.
- Other factors decreased equity by 417,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.45 Million | -54.2% |
| Share Issuances | €21.50 Million | +111.48% |
| Other Changes | €-417.00K | -2.16% |
| Total Change | €- | 122.80% |
Book Value vs Market Value Analysis
This analysis compares ABERA BIOSCIENCE AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.44x to 0.56x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €1.30 | €0.58 | x |
| 2023-12-31 | €0.39 | €0.58 | x |
| 2024-12-31 | €0.56 | €0.58 | x |
| 2025-12-31 | €1.04 | €0.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABERA BIOSCIENCE AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.48x
- Recent ROE (-54.20%) is above the historical average (-119.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -115.50% | 0.00% | 0.00x | 1.17x | €-21.06 Million |
| 2023 | -295.67% | 0.00% | 0.00x | 1.65x | €-17.29 Million |
| 2024 | -12.71% | 0.00% | 0.00x | 1.57x | €-1.97 Million |
| 2025 | -54.20% | 0.00% | 0.00x | 1.48x | €-12.38 Million |
Industry Comparison
This section compares ABERA BIOSCIENCE AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $355,224,390
- Average return on equity (ROE) among peers: -60.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABERA BIOSCIENCE AB (8WK) | €19.29 Million | -115.50% | 0.48x | $11.56 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $205.51 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more